Posts tagged ContraVir Pharma
ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.

Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.

Read More
Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert.

The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in the viral life cycle, he said.

Read More